Get started
Author

Deepika Cattry

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 · Stephen M. Ansell, Alexander M. Lesokhin, et al. · New England Journal of Medicine · 3,563
PDF
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
2016 · Alexander M. Lesokhin, Stephen M. Ansell, et al. · Journal of Clinical Oncology · 1,001
Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies
2014 · Alexander M. Lesokhin, Stephen M. Ansell, et al. · Blood · 126
Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study
2014 · Philippe Armand, Stephen M. Ansell, et al. · Blood · 18
Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma
2017 · Matthew J. Pianko, Samuel A. Funt, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 13
nivolumab In Patients With Relapsed Or Refractory Lymphoid Malignancies And Classical Hodgkin Lymphoma: Updated Results Of A Phase 1 Study (ca209-039) : 010
2015 · John M. Timmerman, Philippe Armand, et al. · Hematological Oncology · 6
The Long PD-1 Receptor Binding Kinetics of Nivolumab May Increase Efficacy of Subsequent Therapy in Relapsed and Refractory Multiple Myeloma Patients
2015 · Samuel A. Funt, David B. Page, et al. · Blood · 4
A phase I dose-escalation study evaluating the effects of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with select relapsed or refractory hematologic malignancies.
2013 · Alexander M. Lesokhin, Martin Gutierrez, et al. · Journal of Clinical Oncology · 2
Sleep Patterns in Elementary School Children (Grades 2-5) and Adolescents (Grade 10)
2011 · Deepika Cattry, Karina Stavitsky, et al.
Works count: 9
Citation count: 4,733
H-index: 6
I10-index: 5
Year
Topic
Type